All In Biotech

Drug Trial Radar · NCT07104617

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Oral TY-302 Capsules Combined With Abiratone Acetate Tablets in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Novel Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Oct 2026

Study completion Nov 2026

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

  • TY-302Drug

    Take the specified dose (75mg or 100mg) orally once a day. Take it on an empty stomach in the morning with about 200 mL of warm water.

  • AbiraptorDrug

    Take orally, 1000mg each time, once a day. Take it on an empty stomach in the morning with warm water, or take it orally at least two hours after fasting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Escalation stage) Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  2. Maximum tolerated dose(MTD)Time frame: Within 28 days of the first dose
  3. (Escalation stage) Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in escalation stage
  4. Adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
  5. (Expansion stage) Progression-free survival (rPFS)Time frame: Up to approximately 21 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.